Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease

Journal of Crohn's and Colitis

Volumn 7, Issue 5, 2013, Pages 369-376

  Assa, Amit ^a,d   Hartman, Corina ^a,d   Weiss, Batia ^b,d   Broide, Efrat ^c,d   Rosenbach, Yoram ^a,d   Zevit, Noam ^a,d   Bujanover, Yoram ^b,d   Shamir, Raanan ^a,d  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adalimumab; Growth; Inflammatory markers; Infliximab; Response

Indexed keywords

ADALIMUMAB; ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; INFLIXIMAB;

ADOLESCENT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD SEDIMENTATION; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HEMOGLOBINS; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875598473     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.006     Document Type: Article

References (50)

1. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
2. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Baldassano R., Braegger C.P., Escher J.C., DeWoody K., Hendricks D.F., Keenan G.F., et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003, 98:833-838.
5. Cezard J.P., Nouaili N., Talbotec C., Hugot J.P., Gobert J.G., Schmitz J., et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003, 36:632-636.
6. Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004, 36:342-347.
7. de Ridder L., Rings E.H., Damen G.M., Kneepkens C.M., Schweizer J.J., Kokke F.T., et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008, 14:353-358.
8. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
9. Hyams J.S., Lerer T., Griffiths A., Pfefferkorn M., Kugathasan S., Evans J., et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
10. de Bie C.I., Hummel T.Z., Kindermann A., Kokke F.T., Damen G.M., Kneepkens C.M., et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011, 33:243-250.
11. Hyams J., Walters T.D., Crandall W., Kugathasan S., Griffiths A., Blank M., et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011, 27:651-662.
12. Chaparro M., Panes J., Garcia V., Mañosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
13. Crombé V., Salleron J., Savoye G., Dupas J.L., Vernier-Massouille G., Lerebours E., et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011, 17:2144-2152.
14. Noe J.D., Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1683-1687.
15. Viola F., Civitelli F., Di Nardo G., Barbato M.B., Borrelli O., Oliva S., et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009, 104:2566-2571.
16. Rosenbach Y., Hartman C., Shapiro R., Hirsch A., Avitzur Y., Shamir R. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010, 55:747-753.
17. Rusell R.K., Wilson M.L., Loganathan S., Bourke B., Kiparissi F., Mahdi G., et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:946-953.
18. Rosh J.R., Lerer T., Markowitz J., Goli S.R., Mamula P., Noe J.D., et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009, 104:3042-3049.
19. Ruemmele F.M., Lachaux A., Cezard J.P., Morali A., Maurage C., Giniès J.L., et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009, 15:388-394.
20. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
21. Kugathasan S., Werlin S.L., Martinez A., Rivera M.T., Heikenen J.B., Binion D.G. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000, 95:3189-3194.
22. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., Dé Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
23. Diamanti A., Basso M.S., Gambarara M., Papadatou B., Bracci F., Noto C., et al. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. Int J Colorectal Dis 2009, 24:19-25.
24. Sinitsky D.M., Lemberg D.A., Leach S.T., Bohane T.D., Jackson R., Day A.S. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol 2010, 25:810-816.
25. Malik S., Wong S.C., Bishop J., Hassan K., McGrogan P., Ahmed S.F., et al. Improvement of growth of children with Crohn's disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011, 52:31-37.
26. Walters T.D., Gilman A.R., Griffiths A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007, 13:424-430.
27. Pfefferkorn M., Burke G., Griffiths A., Markowitz J., Rosh J., Mack D., et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009, 48:168-174.
28. Mackey A.C., Green L., Leptak C., Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48:386-388.
29. Levine A., Griffiths A., Markowitz J., Wilson D.C., Turner D., Russell R.K., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011, 17:1314-1321.
30. Klaasen R., Wijbrandts C.A., Gerlag D.M., Tak P.P. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:359-364.
31. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
32. Konrad A., Lehrke M., Schachinger V., Seibold F., Stark R., Ochsenkühn T., et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19:1070-1074.
33. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
34. Valentini L., Wirth E.K., Schweizer U., Hengstermann S., Schaper L., Koernicke T., et al. Circulating adipokines and the protective effect of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009, 25:172-181.
35. Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S., et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis 2010, 16:630-637.
36. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibodies for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 23:CD006893.
37. Zoli G., Katelaris P.H., Garrow J., Gasbarrini G., Farthing M.J. Increased energy expenditure in growing adolescents with Crohn's disease. Dig Dis Sci 1996, 41:1754-1759.
38. Ballinger A.B., Azooz A., El-Haj T., Poole S., Farthing M.J. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000, 46:694-700.
39. Tracey K.J., Wei H., Manogue K.R., Fong Y., Hesse D.G., Nguyen H.T., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988, 167:1211-1227.
40. DiFedele L.M., He J., Bonkowski E.L., Han X., Held M.A., Bohan A., et al. Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 2005, 128:1278-1291.
41. Thayu M., Denson L.A., Shults J., Zemel B.S., Burnham J.M., Baldassano R.N., et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 2010, 139:430-438.
42. Vasseur F., Gower-Rousseau C., Vernier-Massouille G., Dupas J.L., Merle V., Merlin B., et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010, 105:1893-1900.
43. Parmentier-Decrucq E., Duhamel A., Ernst O., Fermont C., Louvet A., Vernier-Massouille G., et al. Effect of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis 2009, 15:1476-1484.
44. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:11817-11826.
45. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
46. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
47. Lonnkvist M.H., Theodorsson E., Holst M., Ljung T., Hellström P.M. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2011, 46:420-427.
48. Fagan E.A., Dyck R.F., Maton P.N., Hodgson H.J., Chadwick V.S., Petrie A., et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982, 12:351-359.
49. Lonnkvist M.H., Befrits R., Lundberg J.O., Lundahl J., Fagerberg U.L., Hjortswang H., et al. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5years. Eur J Gastroenterol Hepatol 2009, 21:1168-1176.
50. Afif W., Leighton J.A., Hanauer S.B., Loftus E.V., Faubion W.A., Pardi D.S., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009, 15:1302-1307.